Regina Berger

Innsbruck Medical University — Austria

Medicine · Health Sciences

20h-index3.3kcitations102works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(55), Cancer Immunotherapy and Biomarkers(19), PARP inhibition in cancer therapy(19), Immunotherapy and Immune Responses(14), CRISPR and Genetic Engineering(10)

Publications101 total

Supplementary Figure S3 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Figure S1 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Figure S2 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Data from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium
2025Open Access
Supplementary Material 1 from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium
2025Open Access
Assessment of homologous recombination deficiency and BRCA status in ovarian cancer: Analytical performance and relevance of a decentralized NGS assay for comprehensive genomic profiling.
Journal of Clinical Oncology·2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium
Clinical Cancer Research·2025· 1 citedOpen Access
HR-SC—an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
ESMO Open·2025· 1 citedOpen Access
4935 A phase 3 study of pembrolizumab + concurrent chemoradiotherapy for high-risk locally advanced cervical cancer: interim analysis 2 findings
Radiotherapy and Oncology·2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
European Journal of Cancer·2025· 7 citedOpen Access
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology·2024· 45 citedOpen Access
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM
Brachytherapy·2024
Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2024Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2024Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2024Open Access
751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Annals of Oncology·2024· 1 cited
3560: A Phase 3 Study of Pembrolizumab + Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Radiotherapy and Oncology·2024
Supplementary Figure S1 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Ignace Vergote(22), Jalid Sehouli(21), Christian Marth(16), Nicoletta Colombo(14), Sandro Pignata(12), Elena Ioana Braicu(12), Isabelle Ray‐Coquard(9), Antonio González-Martı́n(9), Domenica Lorusso(8), Éric Pujade-Lauraine(8), Nicole Concin(8), Giovanni Scambia(7), Philipp Harter(7), Mansoor Raza Mirza(7), Kathleen N. Moore(7), Sven� Mahner(7), Claudio Zamagni(7), Alain G. Zeimet(7), Carol Aghajanian(6), Aikou Okamoto(6)